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Overactivity of the germinal center (GC) pathway
resulting from accumulation of follicular helper T
(Tfh) cells causes autoimmunity, underscoring the
need to understand the factors that control Tfh cell
homeostasis. Here we have identifed posttranscrip-
tional repression of interferon-g (Ifng) mRNA as
a mechanism to limit Tfh cell formation. By using
the sanroque lupus model, we have shown that
decreased Ifng mRNA decay caused excessive
IFN-g signaling in T cells and led to accumulation of
Tfh cells, spontaneous GC, autoantibody formation,
and nephritis. Unlike ICOS and T-bet deficiency
that failed to rescue several autoimmune manifesta-
tions, interferon-g receptor (IFN-gR) deficiency pre-
vented lupus development. IFN-g blockade reduced
Tfh cells and autoantibodies, demonstrating that
IFN-g overproduction was required to sustain
lupus-associated pathology. Increased IFN-gR
signaling caused Bcl-6 overexpression in Tfh cells
and their precursors. This link between IFN-g and
aberrant Tfh cell formation provides a rationale for
IFN-g blockade in lupus patients with an overactive
Tfh cell-associated pathway.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a heterogeneous auto-
immune disease caused by autoantibodies targeting nuclear
components that affect multiple organs (Rahman and Isenberg,
2008). Clinical manifestations range from skin rashes and
arthritis to life-threatening kidney or cardiovascular involvement.
The relative paucity of effective drugs for lupus indicates that we
need a better understanding of its pathogenesis. Only one new
drug has been approved for lupus by the FDA in the past 50 years
(B cell activating factor of the TNF family [BAFF] monoclonal
antibody [mAb], Belimumab), and this treatment has a relatively
modest effect on disease activity in a small subset of patients
(Liu and Davidson, 2011). Part of the problem is heterogeneity
of causes, with several different pathways contributing to880 Immunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc.disease in different patients: dysregulation in T helper 1 (Th1),
Th17, T follicular helper (Tfh), and T regulatory (Treg) cells, or
excessive production of proinflammatory cytokines and growth
factors such as type I interferon, tumor necrosis factor (TNF),
or BAFF can promote activation of self-DNA-reactive B cells,
triggering lupus (Jacob et al., 2011; Liu and Davidson, 2011;
Rahman and Isenberg, 2008; Ro¨nnblom and Elkon, 2010).
Understanding the molecular and cellular basis of this disease
is critical in targeting specific disease pathways in affected
individuals.
Aberrant formation and accumulation of Tfh cells which
mediate positive selection of B cells that have acquired somatic
mutations in the immunoglobulin (Ig) V region genes has recently
emerged as a key driver of autoantibody-mediated diseases
(Vinuesa et al., 2009). In mice, dysregulated Tfh cell formation
is found in lupus- and type 1 diabetes-prone Roquinsan/san
mice, lupus-prone BXSB-Yaa mice, autoimmune hepatitis-
prone Pdcd1/mice, and in IL-27-dependent pristane-induced
lupus (Aoki et al., 2011; Batten et al., 2010; Bubier et al., 2009;
Subramanian et al., 2006). Dysregulated IL-17-producing GC
Tfh cells have also been proposed to explain lupus in BXD2
mice (Hsu et al., 2008) and autoimmune arthritis of K/BxN mice
(Jacobs et al., 2009). Furthermore, Tfh cells found in extrafollic-
ular foci have been shown to promote autoantibody formation
in MRLlpr mice (Odegard et al., 2008; Poholek et al., 2010). In
humans, associations have been described between increased
circulating Tfh-like cells and SLE (Simpson et al., 2010) and
between an increased proportion of IL-17-producing circulating
Tfh-like cells and juvenile dermatomyositis (Morita et al., 2011).
Homozygosity for the ‘‘san’’ allele of Roquin has recently
emerged as a powerful driver of Tfh cell accumulation (Athana-
sopoulos et al., 2010; Linterman et al., 2009; Vinuesa et al.,
2005).Roquinsan/san mice develop T cell-autonomous accumula-
tion of Tfh cells and lupus. The observations that abrogating Tfh
cell formation prevented lupus in Roquinsan/san mice and that Tfh
cell transfer from these mice induced spontaneous GCs demon-
strated a pathogenic role for Tfh cells in lupus (Linterman et al.,
2009). ROQUIN (Rc3h1) was shown to repress Icos (inducible
T cell costimulator) mRNA posttranscriptionally (Glasmacher
et al., 2010; Yu et al., 2007) through its ability to directly bind
RNA (Athanasopoulos et al., 2010; Glasmacher et al., 2010).
Although Roquinsan-mediated overexpression of ICOS (Yu
et al., 2007) promotes Tfh cell formation and resistance to Treg
cell suppression (Herman et al., 2004), as we show here, it
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Ifng Excess Causes Tfh Cell Accumulation and Lupuscannot alone explain Tfh cell accumulation and lupus develop-
ment. Mice expressing a null allele of Roquin have reduced
GCs and do not develop autoimmunity (Bertossi et al., 2011).
Several factors are likely to contribute to the differing pheno-
types of Roquinsan/san and Roquin/ mice, including redundant
roles of ROQUIN’s ortholog MNAB (Rc3h2) in Icos repression
and additional cell-autonomous roles of ROQUIN inmyeloid cells
(unpublished observations).
Th1 cells and their dominant effector cytokine, IFN-g, have
long been associated with lupus development (Theofilopoulos
et al., 2001). In mice, genetic disruption of Ifngr prevents the
appearance of autoantibodies and kidney damage in MRLlpr
and NZB/W mice (Haas et al., 1998; Schwarting et al., 1998),
and blockade of IFN-g signaling with antibodies against IFN-g
or IFN-gR prevents renal disease in NZB/W mice (Ozmen
et al., 1995). Furthermore, treatment with IFN-gR-Fc reverses
disease in MRLlpr mice (Lawson et al., 2000). In humans, associ-
ations between polymorphisms in IFNG gene and lupus have
been described, including a risk allele leading to elevated
IFN-g expression (Kim et al., 2010). In addition, increased
IFN-g in culture supernatants from peripheral blood mononu-
clear cells (PBMC) of SLE patients strongly correlated with SLE
Disease Activity Index scores (Shah et al., 2010).
Despite these and other studies strongly implicating IFN-g in
SLE pathogenesis and IFN-g mAb (AMG811) treatment having
recently entered phase I clinical trials, the precise pathogenic
mechanism by which this cytokine contributes to disease is
poorly understood. Potential direct mechanisms include end-
organ damage and the induction of B cell Ig switching to IgG2a
in mice, an isotype that is more pathogenic because of its ability
to activate downstream inflammatory cascades (Baudino et al.,
2006; Snapper and Paul, 1987). Nevertheless, the recent demon-
stration that T cell-derived IFN-g does not directly stimulate anti-
body production by human B cells (Morita et al., 2011) suggests
that B cells are not the direct target of the pathogenic role of this
cytokine. Indirect effects of IFN-g on B cells could be mediated
via stimulation of myeloid cells to release BAFF (Harigai et al.,
2008; Scapini et al., 2010). Here we have demonstrated a funda-
mentally different mechanism of action of this important cyto-
kine: IFN-g excess changes the quality of the T cell response,
directly inducing accumulation of Tfh cells. This in turn leads to
aberrant GC formation and autoantibody production.
RESULTS
Accumulation of IFN-g-Producing Cells in Lupus-Prone
Roquinsan/san Mice
Wehave previously reported T cell-autonomous accumulation of
effector CD4+ T cells, including Tfh cells, in lymph nodes and
spleen of Roquinsan/san mice (Linterman et al., 2009; Vinuesa
et al., 2005). Measurement of cytokines in culture supernatants
had also revealed increased IFN-g production by Roquinsan/san
T cells (Vinuesa et al., 2005). To evaluate the relative abundance
of cytokine-producing CD4+ T cells in Roquinsan/san mice, we
enumerated effector and memory (CD44hi) producing IFN-g,
IL-4, and IL-17. IFN-g-producing cells were the most abundant
T cell effectors (13%of total effector andmemory cells), followed
by IL-4+ cells (1%) and IL-17+ cells (0.9%) (Figure 1A; Figure S1A
available online). Total numbers of IFN-g-producing effectorIcells were 7-fold higher than those of wild-type littermates. There
was also a mild increase in the number of IL-17-producing
effector cells in Roquinsan/san mice (Figure S1A). IFN-g was
detected (50–350 pg/ml) in the serum of Roquinsan/san mice
from 7 weeks of age, coinciding with disease onset (Figure 1C);
IFN-g remained below the level of detection in wild-type litter-
mates (Figure 1B).
Next, we evaluated whether the IFN-g-producing cells also
included Tfh cells and found 2- and 3-fold increases in the
number of pre-Tfh and Tfh cells producing IFN-g in Roquinsan/san
mice compared to wild-type littermates (Figure 1D). IFN-g-
producing cells among non-Tfh cell effectors were 9-fold higher
in Roquinsan/san compared with Roquin+/+ mice (Figure 1D).
There was also a higher proportion of natural killer (NK) cells
producing IFN-g in Roquinsan/san mice (Figure S1B).
Roquinsan Delays Ifng mRNA Decay in CD4+ T Cells
Next we investigated whether increased production of IFN-g by
Roquinsan/san T cells was directly caused by the Roquinmutation
in CD4+ T cells or was an indirect consequence of the inflamma-
tory milieu. For this, mixed bone marrow chimeras were con-
structed. Recipient Rag1/ mice were sublethally irradiated
and reconstituted with a 1:1 mix of Roquin+/+ CD45.1 and
Roquinsan/san CD45.2 bone marrow cells. A control set of mice
was reconstituted with a 1:1 mix of Roquin+/+ CD45.1 and
Roquin+/+ CD45.2 bone marrow. The proportion of IFN-g-
producing cells among Roquinsan/san CD45.2 cells was 4-fold
higher than among Roquin+/+ CD45.1 cells in the same chimeric
mice (Figures 2A and 2B). IFN-g expression in naive T cells was
also significantly higher within Roquinsan/san CD45.2 than within
Roquin+/+ CD45.1 cells (Figures 2B and S2A). These data
indicate that the accumulation of IFN-g-producing cells in
Roquinsan/san mice is T cell intrinsic. We previously showed
that the increase in Tfh cells in Roquinsan/san mice is also T cell
intrinsic (Figure S2B).
To investigate whether ROQUIN delays Ifng mRNA decay as
described for Icos mRNA (Glasmacher et al., 2010; Yu et al.,
2007), purified Roquinsan/san and Roquin+/+ naive (CD44lo)
CD4+ T cells were activated with anti-CD3 and anti-CD28 for
24 hr and IfngmRNAwasmeasured by quantitative reverse tran-
scriptase-polymerase chain reaction (RT-PCR). Roquinsan/san
CD4+ T cells expressed 40-fold higher amount of Ifng mRNA
than Roquin+/+ CD4+ T cells at 4 hr (Figure 2C). Next, we inves-
tigated whether accumulation of IfngmRNAwas occurring post-
transcriptionally. Naive CD4+ T cells from Roquinsan/san and
Roquin+/+mice were treated with actinomycin D 3 hr after activa-
tion to inhibit mRNA transcription and IfngmRNA was measured
at different intervals after treatment. Roquinsan/san delayed Ifng
mRNA decay, prolonging its half-life by 9-fold (Figure 2D). By
contrast, no difference in Il2 mRNA decay was observed
between Roquinsan/san and Roquin+/+ T cells (Figure S2C). These
results indicate that excessive IFN-g production in the presence
of Roquinsan is a consequence of failed posttranscriptional
repression of Ifng mRNA.
Deficiency in IFN-gR but Not T-bet or ICOS Rescues
Hypercellularity
The results above suggest that excessive IFN-g production may
contribute to the lupus-like syndrome and autoimmunemmunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc. 881
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Figure 1. Enhanced Production of IFN-g-Producing Cells in Roquinsan/san Mice
(A) Representative flow cytometry plots showing intracellular stains of IFN-g versus IL-17 and IFN-g versus IL-4 gated on CD44hiFoxp3CD4+ T cells (left) and
quantification of total numbers and percentages of IFN-g-, IL-4-, and IL-17-producing cells (right) among CD44hiCD4+ T cells from 8-week-old Roquin+/+ and
Roquinsan/san mice.
(B) IFN-g concentration in serum of 8- to 10-week-old Roquinsan/san and Roquin+/+ littermates analyzed by CBA.
(C) IFN-g concentration in serum of Roquinsan/san of the indicated ages measured by ELISA.
(D) Top: representative flow cytometry plots showing IFN-g versus CD44 gated on non-Tfh (CXCR5PD-1CD4+), pre-Tfh (CXCR5hiPD-1intCD4+), and Tfh
(CXCR5hiPD-1hiCD4+) cells. Bottom: percentages of IFN-g+ cells and mean fluorescence intensity (MFI) of IFN-g expression among non-Tfh (left), pre-Tfh
(middle), and Tfh (right) cells.
Data are representative of two independent experiments with n R 4 mice per group in each experiment. Each dot represents an individual mouse and bars
represent the median value in each group. See also Figure S1. *p < 0.05, ***p < 0.001. ns, not significant.
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Ifng Excess Causes Tfh Cell Accumulation and Lupussusceptibility of Roquinsan/san mice. To test this, we generated
Roquinsan/san mice deficient in either IFN-gR (Roquinsan/san
Ifngr/), IFN-g (Roquinsan/sanIfng/), or T-bet (Roquinsan/san
Tbx21Du/Du) (Jenne et al., 2009). We also generated C57BL/6.882 Immunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc.Roquinsan/san mice lacking ICOS; previously ICOS hemizygosity
(Icos+/) in a mixed C57BL/6.CBA background was shown to
decrease ICOS overexpression (although it remained higher
than the amount of ICOS expressed by wild-type T cells),
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Figure 2. T Cell-Intrinsic Overproduction of
IFN-g in Roquinsan/san Mice Caused by
Increased Ifng mRNA Stability
(A and B) Representative flow cytometry plots (A)
and bar graphs (B) of mixed bone chimeras
containing 1:1 ratio of control Roquin+/+
CD45.1:Roquin+/+ CD45.2 or Roquin+/+ CD45.1:
Roquinsan/san CD45.2 bone marrow 10 weeks after
constitution for the percentage of IFN-g+ cells
among CD4+ T cells (B, top) and MFI of IFN-g
expression in naive (CD44loFoxp3) CD4+ T cells
(B, bottom).
(C) Quantitative RT-PCR analysis of Ifng mRNA
expression in sorted CD44loCD4+ T cells from
8-week-old Roquinsan/san and Roquin+/+ mice
cultured for the indicated times with anti-CD3,
anti-CD28 in the presence of IL-12p70 and anti-
IL-4 for 4 hr.
(D)Remaining IfngmRNA inactivatedRoquinsan/san
and Roquin+/+ cells treated with actinomycin D
and measured at the indicated times via quanti-
tative RT-PCR. Amount of Ifng mRNA at time
0 in each group was assigned as 100%.
Trendlines were fitted to predict Ifng mRNA half-
life (T1/2).
Data are representative of four (A and B) inde-
pendent experiments with nR 4 mice per group in
each experiment. Each dot represents an indi-
vidual mouse and bars represent the median value
in each group. In (C) and (D), data shown represent
mean values ± SD with n = 3 in two independent
experiments. See also Figure S2. *p < 0.05,
**p < 0.005.
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Ifng Excess Causes Tfh Cell Accumulation and Lupusreducing Roquinsan/san splenomegaly and lymphadenopathy (Yu
et al., 2007).
Lack of IFN-gR signaling in Roquinsan/sanIfngr/ mice
prevented hypercellularity and splenomegaly (Figures 3A).
Roquinsan/sanIfngr/ mice also showed a significant reduction
in the percentage of effector and memory (CD44hi) CD4+
T cells, but maintained the elevated Treg cell numbers typical
of Roquinsan/san mice (Figure 3A). By contrast, complete defi-
ciency of either T-bet or ICOS failed to rescue the splenomegaly
and effector and memory T cell expansion (Figures 3A and S3A).
Of note, Roquinsan/sanTbx21Du/Du mice still overproduced IFN-g
compared to wild-type mice (Figure S3B), suggesting that
mutant ROQUIN leads to IFN-g overproduction independently
of T-bet-mediated transcriptional control. In contrast to the
effect of ICOS hemizygosity in Roquinsan/san mice, complete
lack of ICOS not only failed to reduce splenomegaly but
further increased splenic cellularity (Figures 3A and S3C) and
led to the production of homogeneous nuclear antinuclear
antibodies (ANAs; data not shown), different from the mixed
nuclear and cytoplasmic pattern typical of Roquinsan/san mice.
This is likely to be explained by the observed reduction in
Foxp3+CD4+ Treg cell numbers in the absence of ICOS in
Roquinsan/san mice (Figures 3A and S3C) plus defective
Treg cell function that characterizes ICOS-deficient Treg cells
(Herman et al., 2004).IExcessive IFN-g Signaling Promotes Accumulation
of Tfh Cells and GC B Cells and Triggers Lupus
Next we sought to investigate a possible link between IFN-g
overproduction and the aberrant Tfh cell accumulation and
spontaneous GC formation in Roquinsan/san mice. Tfh and GC
B cells were enumerated by flow cytometric staining. Lack of
IFN-g signaling significantly reduced total CD4+ T cells, Tfh,
and GC B cell numbers in Roquinsan/sanIfngr/ mice (Figures
3B and 3C). Complete IFN-g deficiency in Roquinsan/sanIfng/
mice also reduced the proportion of Tfh and GC B cells (Fig-
ure S3D). Consistent with the described roles for IFN-g in switch-
ing to IgG2a (IgG2c in C57BL/6 mice) (Huang et al., 1993;
Snapper and Paul, 1987), IgG2a+ GC B cells were also reduced
or absent in Roquinsan/san mice lacking IFN-gR or IFN-g (Figures
3B, 3C, and S3D).
Given our previous observation of a causal relationship
between Tfh cell accumulation and lupus when ROQUIN
is mutated (Linterman et al., 2009), we investigated the
consequences of IFN-g signaling in Roquinsan/san autoimmune
disease. Assessment of renal histology revealed that all
Roquinsan/san mice had multiple mesangial electron-dense
deposits, whereas only one out of six Roquinsan/sanIfngr/
mice had minor interstitial mesangial deposits compared to
aged-matched 8-month-old Roquinsan/san mice (Figure 4A).
Lack of IFN-gR also reduced nephritis (Figure 4C) and preventedmmunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc. 883
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Figure 3. IFN-gRDeficiency inRoquinsan/san
Mice Reduces Hypercellularity and Tfh and
GC B Cells
(A) Quantification of total numbers of splenocytes
(top), percentages of effector and memory CD4+
T cells (CD44hiFoxp3; middle) and Treg cells
(CD44intFoxp3+; bottom) from 8-week-old
Roquin+/+,Roquinsan/san,Roquinsan/sanIfngr/, and
Roquinsan/sanIcos/ mice (data for Roquinsan/san
Tbx21Du/Du are listed in Figure S3A).
(B and C) Representative flow cytometry plots
(B) and quantification of total numbers (C) of
CD4+ T cells, Tfh cells identified as CXCR5hi
PD-1hi (gated on CD44hiFoxp3CD4+ cells), GC
B cells identified as GL-7+FAS+ (gated on B220+
cells), and IgG2a+ cells (gated on GC B cells)
from 8-week-old Roquin+/+, Roquinsan/san, and
Roquinsan/sanIfngr/ mice.
Data are representative of four independent
experiments with n R 3 mice per group in each
experiment. Each dot represents an individual
mouse and bars represent the median value
in each group. See also Figure S3. *p < 0.05,
**p < 0.005. ns, not significant.
Immunity
Ifng Excess Causes Tfh Cell Accumulation and LupusANA formation (Figures 4B and 4C). These results contrast with
the lack of contribution of IL-21 to the hypercellularity, Tfh and
GC B cell numbers, and autoantibodies in these mice (Linterman
et al., 2009).
We next investigated whether disease can be ameliorated by
blocking IFN-g. For this, 5-week-old female mice, which had
already developed ANAs, were treated with 500 mg anti-IFN-g
monoclonal every 3 days for 3 weeks. At the end of this treat-
ment, anti-IFN-g-treated mice had reduced numbers of effector
andmemory cells, Tfh cells, andGCBcells, and significantly less
ANAs than mice treated with isotype control (Figures 4D–4F and
S4A). In addition, autoantibody concentration in anti-IFN-g-884 Immunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc.treated mice had reverted to the
concentration found in wild-type mice
(Figure 4F). Together, these results
demonstrate that IFN-g overproduction
leads to a pathogenic and lupus-inducing
Tfh cell response and is required to
sustain this aberrant response.
T Cell-Specific IFN-gR Deficiency Is
Sufficient to Reduce Tfh Cell
Accumulation
To investigate whether IFN-g was
acting predominantly on CD4+ T cells to
induce the aberrant Tfh cell and GC
phenotype, we generated chimeric mice
in which only T cells would lack
IFN-gR signaling. For this, sublethally
irradiated Rag1/ recipient mice were
reconstituted with a 70%:30% mix of
Roquinsan/sanTcra/ and Roquinsan/san
Ifngr/ bone marrow cells. A control
set of chimeras with intact IFN-gR
signaling was constructed with a70%:30% mix of Roquinsan/sanTcra/ and Roquinsan/san bone
marrow. Sets of 100% chimeras reconstituted with either
Roquin+/+, Roquinsan/san, or Roquinsan/sanIfngr/ bone marrow
were also used as controls.
Selective deficiency in IFN-gR in T cells reduced Tfh cell
accumulation in Roquinsan/san mice to the amount found in
Roquinsan/sanIfngr/ mice and Roquin+/+ mice, indicating that
increased IFN-gR signaling in T cells leads to Tfh cell accumula-
tion in Roquinsan/san mice (Figure 5A). IFN-gR signaling in T cells
also contributed to the increase in GC B cells observed in
Roquinsan/san mice: fewer GL-7+FAS+ B cells were observed in
Roquinsan/san chimeras lacking IFN-gR only in T cells although
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Figure 4. IFN-gR Deficiency Ameliorates
the Autoimmune Phenotype ofRoquinsan/san
Mice
(A and C) Representative images of kidney
sections (A) stained with H&E (left) or viewed under
an electron microscope (right) and scores of
nephritis severity (C, left) according to the criteria
given in Table S1 from 6-month-old Roquin+/+,
Roquinsan/san, and Roquinsan/sanIfngr/ mice.
Electron-dense Ig deposits are indicated with
arrows.
(B and C) Representative images (B) and quanti-
fication of fluorescent intensity (C, right) of ANA
IgG autoantibodies detected with Hep-2 slides in
serum from 8-week-old Roquin+/+, Roquinsan/san,
and Roquinsan/sanIfngr/ mice.
(D–F) Representative flow cytometry plots (D) and
quantification of percentages and total numbers of
Tfh cells (E, top), GC B cells (E, bottom), and
concentration of ANA Ig serum autoantibodies (F)
from Roquin+/+ mice (untreated) and female
Roquinsan/san mice prior to treatment and
after treatment with rat IgG1 isotype control or
anti-IFN-g every 3 days for 3 weeks starting at
5 weeks of age.
Scale bars represent 100 mm for H&E in all panels;
5 mm for electron microscopy in all panels; 200 mm
for Hep-2 staining in all panels. Data are repre-
sentative of two independent experiments with
n R 4 mice per group in each experiment. Each
dot represents an individual mouse and bars
represent the median value in each group. See
also Figure S4. *p < 0.05, **p < 0.005. ns, not
significant.
Immunity
Ifng Excess Causes Tfh Cell Accumulation and LupusGC B cells were higher than in mice lacking IFN-gR signaling in
all cells (Figure 5A).
To formally test whether excessive IFN-g signaling also acts
directly on GC B cells, we set up mixed chimeras in which only
B cells would lack IFN-gR signaling by reconstituting sublethally
irradiated Rag1/ recipient mice with a 70%:30% mix of
Roquinsan/sanCd79aken/ken and Roquinsan/sanIfngr/ bone
marrow cells. Although both Tfh and GC B cells were reduced
in these chimeras (Figure S5A), the same reduction was seen
in control recipients of Roquinsan/sanCd79aken/ken:Roquinsan/san
bone marrow cells. The number of B220+ cells in recipients of
bone marrow containing Cd79aken/ken cells was 20% comparedImmunity 37, 880–892, Nwith other chimeric groups (Figure S5B),
suggesting that the correction of the Tfh
cell and GC phenotype is a consequence
of the significantly reduced B cell
numbers in these chimeric mice and
these chimeras cannot be used to draw
conclusions on B cell-intrinsic effects.
ANAs were not measured because
the irradiation and reconstitution
process induces autoantibodies. IFN-gR
signaling is known to exert important
effects on myeloid cells. All myeloid cell
subsets were found to be expanded in
total numbers in Roquinsan/san spleens;this effect was T cell driven because myeloid cell expansion
and splenic hypercellularity were completely corrected in
Roquinsan/sanRag1/ mice (Figures S5C and S5D) but not in
Roquinsan/sanCd79aken/ken (B cell-deficient) mice (data not
shown).
To investigate whether excessive IFN-gR signaling in T cells is
sufficient to drive autoantibody formation, we transferred 53 106
Roquinsan/san T cells sufficient or deficient in IFN-gR signaling
together with 7 3 106 wild-type B cells into Rag1/ mice.
Eight weeks after transfer, ANAs were higher in recipients of
Roquinsan/san T cells than in recipients of Roquinsan/sanIfngr/
T cells; the latter were comparable to recipients of wild-typeovember 16, 2012 ª2012 Elsevier Inc. 885
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Figure 5. IFN-gR Signaling in T Cells Is
Required for Tfh and GC B Cell Accumula-
tion in Roquinsan/san Mice
(A) Representative flow cytometry plots (left) and
quantification of percentages (right) of Tfh and GC
B cells from mixed bone chimeras of indicated
genotypes 10 weeks after reconstitution.
(B) Representative flow cytometry plots (top) and
quantification (bottom) of Tfh (%), MFI of Bcl-6
expression in Tfh cells, and concentration of
ANA Ig serum autoantibodies in Rag1/ mice
transferred with 5 3 106 sorted Roquin+/+,
Roquinsan/san, or Roquinsan/sanIfngr/ CD4+
T cells and 7 3 106 sorted Roquin+/+B220+ cells
8 weeks after adoptive cell transfer.
Data are representative of two independent
experiments with n R 4 mice per group in each
experiment. Each dot represents an individual
mouse and bars represent the median value in
each group. See also Figure S5. *p < 0.05,
**p < 0.005, ***p < 0.001. ns, not significant.
Immunity
Ifng Excess Causes Tfh Cell Accumulation and LupusT cells (Figure 5B). The increase in autoantibodies in recipients of
Roquinsan/san T cells was paralleled by a substantial increase in
Tfh cells, which expressed higher amount of B cell lymphoma
6 (Bcl-6) (Figure 5B). Together, these results suggest that over-
production of IFN-g and IFN-gR signaling in T cells are key
drivers of the Tfh cell accumulation and autoimmune phenotype,
but a contribution of IFN-gR signaling inmyeloid cells and B cells
is likely to accelerate or exacerbate the disease.
Next we asked whether the aberrant Tfh cell response arising
from an overactive IFN-g response is unique to the sanroque
mouse model or shared by other lupus-prone mice. Fas/
mice develop early- or late-onset lupus depending on whether886 Immunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc.they are bred on an MRL or B6 back-
ground, respectively (Andrews et al.,
1978; Warren et al., 1984), and IFN-g
blockade experiment has demonstrated
that this treatment ameliorates lupus
pathology (Lawson et al., 2000). MRLlpr
mice with defective Fas signaling also
have expanded Tfh cells located at
extrafollicular sites that are pathogenic
(Odegard et al., 2008). Analysis of IFN-
g-producing cells in Fas/mice revealed
an increase in IFN-g-producing cells
among total effector and memory
(Figures 6A and S6A), non-Tfh, and Tfh
cells (Figure 6B). This was accompanied
by a 3-fold increase in total effector and
memory (CD44hi) CD4+ T cells, 9-fold
increase in Tfh cells (PD-1hiCXCR5hi),
11-fold increase in GC B cells, and
increased ANAs compared with wild-
type controls (Figures 6C, 6D, and S6B).
Our data together with evidence that
SAP deficiency—known to selectively
eliminate Tfh cells (Cannons et al., 2010;
Linterman et al., 2009; Qi et al., 2008)—
abrogates lupus in Fas/ mice (Komori
et al., 2006) further support the notion that the pathogenic
IFN-g response is linked to the aberrant Tfh cell response.
Excessive IFN-g Signaling Enhances Bcl-6 Expression
and Increases Proliferation of Early CD4+ T Cell
Effectors
IFN-g has been described to have paradoxical proproliferative
and proapoptotic effects in CD4+ and CD8+ T cells (Li et al.,
2007; Shi et al., 2002). Intracellular staining with Ki-67 and with
Annexin V and 7AAD was used to investigate proliferation and
survival, respectively. Lack of IFN-gR signaling did not have
any effects on Tfh cell proliferation but significantly decreased
AC
D
B
Figure 6. Increased Numbers of IFN-g-Producing Cells in Fas–/– Mice Is Associated with Increased Tfh Cells
(A) Quantification of percentages of IFN-g-, IL4-, and IL-17-producing cells among CD44hiCD4+ T cells from 10-week-old Fas/ and Fas+/+ mice.
(B) Quantification of percentages of IFN-g-producing cells among non-Tfh (left) and Tfh (right) cells from 10-week-old Fas/ and Fas+/+ mice.
(C and D) Representative flow cytometry plot (C, left) and quantification of percentages and total numbers (C, right) of Tfh and GC B cells gated on GL7+B220+ of
all lymphocytes, and concentration of ANA Ig serum autoantibodies (D) from 10-week-old Fas/ and Fas+/+ mice.
Data are representative of two independent experiments with nR 4mice per experiment. Each dot represents an individual mouse and bars represent themedian
value in each group. See also Figure S6. *p < 0.05, **p < 0.005.
Immunity
Ifng Excess Causes Tfh Cell Accumulation and Lupusthe proportion of cycling naive (CD44loFoxp3) and non-Tfh
cell effectors (Figure 7A). IFN-gR deficiency did not have any
influence in the survival of total CD4+ T cells or Tfh cells
(Figure S7A).
Several studies have shown that Bcl-6 is required for the
formation of Tfh cells (Johnston et al., 2009; Nurieva et al.,
2009; Yu et al., 2009), so we asked whether excessive IFN-gRIsignaling altered Bcl-6 expression in Roquinsan/san mice.
Roquinsan/san mice were found to express significantly higher
amount of Bcl-6 (an isotype control for the Bcl-6 stain is shown
in Figure S7B). Bcl-6 overexpression was observed in both
PD-1hiCXCR5hi GC Tfh cells and PD-1intCXCR5hi cells that
include Tfh cell precursors (Figure 7B; Lee et al., 2011). Lack of
IFN-gR signaling completely normalized Bcl-6 expression inmmunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc. 887
B0 102 103 104 105
0
102
103
104
105
P
D
-1
 
CXCR5 
Roquinsan/san Ifngr-/- 
Roquinsan/san
Roquin+/+
Gated on CD44lo
0
200 
400 
600 
800 
1000 
B
cl
-6
 M
FI
0
500 
1000 
1500 
B
cl
-6
 M
FI
 
* 
* 
** 
ns 
Ifngr-/- 
Roquin+/+ Roquinsan/san 
0 102 103 104 105
0
20
40
60
80
100
   
M
ax
 (%
) 
Bcl-6 
0 102 103 104 105
0
20
40
60
80
100
0
1
2
3
4
5
K
i-6
7+
 (%
) * 
ns 
0 
10 
20 
30 
40 
K
i-6
7+
 (%
) ** 
** 
Roquinsan/san Ifngr-/- 
Roquinsan/san
Roquin+/+
A
0 102 103 104 105
0
20
40
60
80
100
0 102 103 104 105
0
20
40
60
80
100
Ki-67 
M
ax
 (%
) 
Gated on CD44lo Gated on CD44hi 
25 
0
5
10 
15 
20 
K
i-6
7+
 (%
)
ns 
* 
Ifngr-/- 
Roquin+/+ Roquinsan/san 
Ifngr-/- 
Roquin+/+ Roquinsan/san 
Ifngr-/- 
Roquin+/+ Roquinsan/san 
CD44hi cells Tfh cells CD44lo cells 
CD28 CD28
C
0 
1 
2 
3 
4 
* 
*** 
** 
*** 
R
el
at
iv
e 
bc
l6
 m
R
N
A 
ex
pr
es
si
on
24 hours 
0 
2 
4 
6 
8 
*** ** 
*** ns 
72 hours 
rIL-6 rIFN-NIL rIL-6 rIFN-NIL rIL-6 rIFN-NIL rIL-6 rIFN-NIL 
Figure 7. IFN-gR Signaling Enhances Bcl-6
Expression and Proliferation of Effector
and Memory CD4+ T Cells
(A) Histograms (top) and bar graphs (bottom) of
Ki-67 expression in naive (CD44lo; left) and
effector andmemory (CD44hi; middle) CD4+ T cells
and Tfh cells (right) from 8-week-old Roquin+/+,
Roquinsan/san, and Roquinsan/sanIfngr/ mice.
(B) Flow cytometry plot, histograms, and
bar graphs showing Bcl-6 expression (MFI) in
pre-Tfh and Tfh cells from 8-week-old Roquin+/+,
Roquinsan/san, and Roquinsan/sanIfngr/ mice.
(C) Quantitative RT-PCR analysis of bcl6 mRNA
expression in sorted CD44loCD4+ T cells from
8-week-old Roquin+/+ mice activated for 24 (left)
and 72 (right) hr with anti-CD3, anti-IL-4, anti-
TGF-b in the presence or absence of CD28 and
rIFN-g or rIL-6.
Data are representative of three (A and B) inde-
pendent experiments with nR 4 mice per exper-
iment. Each dot represents an individual mouse
and bars represent the median value in each
group. In (C), data shown represent mean values ±
SD with n = 5 in two independent experiments.
See also Figure S7. *p < 0.05, **p < 0.005,
***p < 0.001. ns, not significant.
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Ifng Excess Causes Tfh Cell Accumulation and Lupusboth Tfh cell-related subsets in Roquinsan/san mice (Figure 7B).
Bcl-6 expression was not altered in Roquinsan/san naive
(CD44lo) or non-Tfh (CXCR5loPD-1lo) cells (Figure S7C). We
confirmed previous findings demonstrating that 5 ng/ml rIFN-g
can induce bcl6 mRNA in anti-CD3-activated T cells within
24 hr, regardless of CD28 costimulation (Figure 7C). Bcl-6
upregulation was maintained for 72 hr in the presence of CD28
costimulation to amount comparable to those induced by rIL-6
but not in the absence of CD28 (Figure 7C). Collectively, these888 Immunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc.data suggest that IFN-g promotes prolif-
eration of naive and activated CD4+
T cells and enhances Bcl-6 expression
in Tfh cells and their precursors. Of
note, IFN-gR signaling had no effect
on Bcl-6 expression in GC B cells
(Figure S7D).
DISCUSSION
IFN-g has been long associated with
lupus pathology but its precise role in
disease pathogenesis has been unclear.
Here we have discovered how excessive
IFN-g acts in a reliable model of lupus: by
promoting Tfh cell accumulation. Limiting
Tfh cell numbers has emerged as an
important mechanism to control GC
output and maintain tolerance to nuclear
antigens. These findings have clinical
implications because subsets of patients
with lupus and other autoimmune
disorders have been shown to bear
biomarkers of an overactive Tfh cell orGC pathway (Morita et al., 2011; Simpson et al., 2010). We
speculate that IFN-g neutralization may be particularly effective
in this patient group.
IFN-g promotes T cell proliferation from the naive stage and
augments Bcl-6 expression in Tfh cells and their precursors.
These effects are likely to enhance the formation and possibly
the maintenance of Tfh cells: Bcl-6 transgenic mice develop
T cell-derived tumors bearing Tfh cell markers (Lin et al., 2011).
Bcl-6 acts in a dose-dependent manner in the regulation of
Immunity
Ifng Excess Causes Tfh Cell Accumulation and Lupusdownstream targets, and Tfh cells hemizygous in Bcl-6 form
decreased Tfh cells (Yu et al., 2009). Excessive Bcl-6 expression
is predicted to repress Blimp-1 expression in activated T cells,
favoring this fate over that of non-Tfh cell effectors (Choi et al.,
2011). We and others have shown that incubation of anti-CD3-
activated T cells with rIFN-g induces upregulation of Bcl-6
(Zhou and Ono, 2005). This upregulation is thought to occur via
pSTAT-1 binding to an interferon-responsive element in exon 1
of bcl6 (Zhou and Ono, 2005). The proproliferative effect of
IFN-g is probably a consequence of this cytokine’s ability to
enhance T cell costimulation and antigen presentation by
plasmacytoid dendritic cells (pDCs) (Bratke et al., 2011) and
myeloid DCs (Vieira et al., 2000).
The relationship between Th1 cells and Tfh cells has been
controversial. Although Tfh cells are driven by their own tran-
scriptional regulator, Bcl-6 (Johnston et al., 2009; Nurieva
et al., 2009; Yu et al., 2009), description of Tfh cells capable of
producing IFN-g (Reinhardt et al., 2009; Yusuf et al., 2010) led
to the hypothesis that Tfh cells could derive from Th1 as well
as other T helper cell lineages (Crotty, 2011). More recently,
the report of very early—at the time of the first or second divi-
sion—and dichotomous polarization into either Bcl-6-express-
ing Tfh cells or Blimp-1-expressing non-Tfh cell effectors (Baum-
johann et al., 2011; Choi et al., 2011) has suggested that Tfh cells
originate independently from other effectors including Th1 cells.
Importantly, the effect of IFN-g described here acts indepen-
dently of T-bet; in fact, T-bet deficiency in Roquinsan/san mice
did not ameliorate lupus. T-bet-independent IFN-g production
as observed in Roquinsan/san has been shown to occur physio-
logically downstream of IL-12 or STAT-4, BAFF, CD8+ T cell-
derived IFN-g or gd T cell-derived IFN-g (Chen et al., 2007;
Park et al., 2004; Scapini et al., 2010; Szabo et al., 2002).
A question that arises is whether expanded Th1 cells in
Roquinsan/san mice are also contributing to the lupus phenotype
independently of Tfh cells. Our previous experiments suggest
that this is unlikely: selective abrogation of Tfh cell formation
via genetic deficiency in SLAM-associated protein (SAP)—which
did not reduce Th1 cells—in sanroquemice resulted in complete
abrogation of autoantibody formation and lupus disease,
although it did not correct the splenomegaly or the hypergam-
maglobulinemia (Linterman et al., 2009). This, together with
the demonstration in the same study that passive transfer of
Roquinsan/san Tfh cells promotes spontaneous GC formation,
suggests that Tfh cells but not Th1 cells are responsible for the
aberrant B cell activity leading to autoantibody production and
kidney disease in Roquinsan/san mice (Linterman et al., 2009).
However, it is possible that Th1 cells, and not Tfh cells, are
responsible for the hypercellularity of secondary lymphoid
tissues, which is not an autoimmune manifestation per se.
As opposed to the amelioration of lymphoid organ cellularity
observed by halving the gene dose of Icos in Roquinsan/san
CBAxB6 mice, complete ICOS deficiency failed to reduce
splenomegaly. Interestingly, the pattern of the autoantibodies
also changed, suggesting that an additional mechanism of auto-
antibody formation is triggered by ICOS deficiency. The reduced
number of Treg cells in Roquinsan/sanIcos/ mice together with
impaired suppressive function of Treg cells lacking ICOS (Her-
man et al., 2004) is likely to account for the disease exacerbation.
The corollary from this and our previous study is that althoughIexcessive ICOS signaling contributes to Tfh cell expansion, it
is not the primary cause of disease pathogenesis, which we
show here stems from excessive Ifng mRNA production. This
is consistent with the finding that IFN-g deficiency alone could
not completely correct Tfh cell numbers, suggesting that other
factors including ICOS overexpression lead to this phenotype.
Our work reveals a second target of mRNA regulation by
ROQUIN, only known to date to regulate Icos mRNA posttran-
scriptionally (Athanasopoulos et al., 2010; Glasmacher et al.,
2010; Yu et al., 2007). The increased Ifng mRNA half-life in
Roquinsan/san T cells compared to Roquin+/+ controls, together
with the demonstrated T cell-autonomous nature of Ifng mRNA
accumulation from the naive T cell stage, suggest that Ifng and
Icos mRNA may be deregulated by Roquinsan by a similar
mechanism.
Our work also illuminates fundamental Tfh cell biology: IFN-g
deficiency did not impair a Tfh cell response against immuniza-
tion with foreign antigen (data not shown); nevertheless, exces-
sive IFN-g led to Tfh cell accumulation. Our findings underscore
the potential danger of excessive IFN-g production during viral
infection, and therefore, the importance of IFN-g regulation to
offset this risk of developing GC-driven autoimmunity. Our
observation that costimulation was required to maintain IFN-g-
driven Bcl-6 expression is consistent with the notion that uncon-
trolled or chronic stimulation with foreign pathogens may trigger
a pathogenic autoimmune response. This observation is also
consistent with our previous findings showing that CD28 defi-
ciency prevents spontaneous Tfh cell and GC B cell formation
and lupus development in sanroque mice (Linterman et al.,
2009). Furthermore, our results provide an explanation for the
intriguing observation made by us and others that, unlike
sustained high production of IL-4 and IL-21 as Tfh cells terminally
differentiate, IFN-g production is lowered on a per cell basis in
GC Tfh cells compared to their precursors (reviewed in Yu and
Vinuesa, 2010). The added layer of IFN-g repression revealed
by our study—control of IfngmRNA stability in T cells—emerges
as a potent mechanism to prevent accumulation of Tfh cells in
the context of infection and as a key checkpoint to prevent
GC-derived autoimmunity.
EXPERIMENTAL PROCEDURES
Mice
Roquinsan/san C57BL/6 mice crossed to Ifngr/, Ifng/, Tbx21Du/Du (Jenne
et al., 2009), Icos/, Tcra/, Cd79aken/ken, and Rag1/; C57BL/6.Fas/
(Adachi et al., 1996) and C57BL/6 mice were bred and maintained in
specific-pathogen-free conditions at the Australian National University
Bioscience Facility. All procedures carried out were approved by the Australian
National University’s Animal Experimentation Ethics Committee (AEEC).
Generation of Bone Marrow Chimeras
Recipient Rag1/mice were sublethally irradiated with 500 Rad and reconsti-
tuted via intravenous (i.v.) injection with 2 3 106 bone marrow-derived hema-
topoetic stem cells of the genotypes indicated in the text. Chimeric mice were
maintained on antibiotics for 6 weeks after reconstitution and experiments
were performed 8 to 10 weeks after reconstitution.
Flow Cytometry
Antibodies are listed in Supplemental Data. The staining procedure has been
previously described (Lee et al., 2011) except for the detection of cytokine-
producing Tfh cells, cells were stained with 1 hr CXCR5-biotin and 30 min
SA-PE Cy7 prior to PMA, ionomycin, and Golgi stop stimulation. For Annexinmmunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc. 889
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Ifng Excess Causes Tfh Cell Accumulation and LupusV or 7AAD staining, cells were incubated at 37C for 2 hr before staining for
surface molecules and then Annexin V-Pacific Blue was added for 15 min in
the dark at room temperature (RT) in Annexin V binding buffer (Biolegend).
Cells were stained with 7AAD immediately before data acquisition. Flow cy-
tometry data were acquired on an LSRII (BD) flow cytometer and analyzed
with Flowjo version 8 (Tree Star).
Cell Sorting, Culture, and Stimulation
Single-cell suspensions were prepared and resuspended in ice-cold sorting
buffer (1% FCS, 0.1% NaN3 in PBS) for sorting with a Flow cytomtery Aria II
(BD). 5 3 105 naive (CD44loCD25) sorted CD4+ T cells were activated in
Th1 cell polarizing conditions (10 ng/ml recombinant mouse IL-12p70
[eBioscience] and 10 mg/ml anti-IL-4 [Biolegend]) in RPMI medium for 0, 1,
2, 4, 6, 12, and 24 hr at 37C in triplicate in 24-well plate (Corning) precoated
with 5 mg/ml anti-CD3 (BD) and 2.5 mg/ml anti-CD28 (BD). For some experi-
ments, naive cells were cultured in 5 mg/ml anti-CD3, 10 mg/ml anti-IL-4, and
10 mg/ml anti-TGF-b (BioXcell) in the presence or absence of 2.5 mg/ml anti-
CD28, 5 ng/ml rIFN-g (PeproTech), or 30 ng/ml rIL-6 (R&D Systems) for 24
and 72 hr at 37C. Cell culture supernatants were then aspirated and cell
pellets were stored in TRIzol (Invitrogen) for real-time RT-PCR analysis.
Actinomycin D Treatment
For actinomycin D treatment, 5 3 105 naive CD4+ T cells were cultured and
activated in the presence of 5 mg/ml anti-CD3, 2.5 mg/ml anti-CD28, and
10 ng/ml IL-12p70 for 16 hr in a 24-well plate followed by treatment with
10 mg/ml actinomycin D (transcriptional inhibition reagent, Sigma Aldrich) in
triplicate for 0, 0.5, 1, and 3 hr.
cDNA Preparation and Real-Time RT-PCR
RNA was extracted with the TRIzol extraction method, and cDNA was
prepared with M-MLV reverse-transcription with oligo(dT) (Invitrogen). Quanti-
tative PCR was performed with a ABI Prism detection system (model 7900;
Applied Biosystems) with Power SYBR Green PCR Master Mix (Applied
Biosystem). Primer sequences are indicated in the Supplemental Data.
Adoptive Cell Transfer Experiments
CD4+ T cells and B220+ cells from spleens and lymph nodes of Roquin+/+,
Roquinsan/san, and Roquinsan/sanIfngr/ were sorted as described in the
previous section. 5 3 106 CD4+ T cells and 7 3 106 B220+ sorted cells were
injected i.v. into Rag1/ recipients. Experiments were performed 8 weeks
after transfer.
Anti-IFN-g Treatment
5-week-old female Roquinsan/san mice were bled prior to treatment and then
injected i.v. with 500 mg anti-IFN-g monoclonal (BioXcell, clone: XMG 1.2) or
500 mg rat IgG1 Isotype control mAb (BioXcell) every 3 days for 3 weeks.
Assessment of Renal Pathology
Kidneys slides were prepared and stained with hematoxylin and eosin (H&E)
and 2% aqueous uranyl acetate for electron microscopy as described
previously (Linterman et al., 2009). Nephritis severity was assessed by histo-
logical analysis and scored blindly according to the criteria in Table S1.
ANA Assessment
Serum was obtained from 8- to 10-week-old mice by eye or cardiac bleed and
used for immunoflourescence staining on fixed Hep-2 slides (Antibodies, Inc.)
as previously described (Linterman et al., 2009). In brief, slides were incubated
with 20 ml serum for 45 min followed by 20 ml goat anti-mouse IgG-A488
(Invitrogen) incubation for 20 min. Slides were viewed with an Olympus micro-
scope (model TH4-200; Olympus Optical) at 203 magnification and fluores-
cent intensity of the autoantibodies was measured by Image J software
(National Institutes of Health, USA) on 20 randomly selected 2,400 mm2 regions
of clustered Hep-2 cells. Concentration of ANA Ig autoantibodies in serum
were also measured with Mouse ANAs Total Ig ELISA kit (Alpha Diagnostic)
according to the manufacturer’s instructions. In brief, 100 ml serum and stan-
dards were incubated in 96-well plates precoated with purified extractable
nuclear antigens for 60 min at RT. Then, 100 ml of goat anti-mouse Ig coupled
with horseradish peroxidase was added and incubated for 30 min. This is890 Immunity 37, 880–892, November 16, 2012 ª2012 Elsevier Inc.followed by 100 ml 3,30,5,50-tetramethylbenzidine (TMB) substrate incubation
for 15 min in the dark and 100 ml stop solution. Plates were then read at
405 nm with a Infinite 200 Pro microplate reader (Tecan). The ANA Ig autoan-
tibodies concentration were calculated relative to mouse ANA standards.
Serum Cytokine Detection
IFN-g concentration in serum was evaluated by cytometric bead array (CBA;
Mouse Th1 or Th2 cytokine CBA kit, BD) according to the manufacturer’s
instructions. 50 ml serum and standards were added into 50 ml of cytokine
capture bead suspension together with 50 ml PE-detection reaction and
incubated for 2 hr at RT in the dark. Data were acquired with a LSRII flow
cytometer. Detection of serum IFN-g concentration in mice at different stages
of disease was performed with the Mouse IFN-g ELISA kit II (BD) according to
the manufacturer’s instructions. In brief, 50 ml serum and standards were
added into 96-well plates precoated with anti-mouse IFN-g monoclonal and
incubated for 2 hr at RT. Then, 100 ml biotinylated anti-mouse IFN-gwas added
and incubated for 1 hr. This is followed by 100 ml TMB substrate incubation for
30 min in the dark. Finally, 50 ml stop solution was added and plate was read at
450 nm. The IFN-g concentration in serum was calculated according to the
standard curve generated.
Statistical Analysis
All data were analyzed with nonparametric Mann-Whitney test (U test) except
mixed bonemarrow chimera experiments, in which paired Student’s t test was
used; and in vitro culture experiments, in which unpaired t test was used. All
statistical analysis was performed with Prism software (version 5, GraphPad
Software). Statistically significant differences are indicated as *p % 0.05,
**p% 0.01, and ***p% 0.001; and ns = not significant.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.immuni.2012.10.010.
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